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PURPOSE. Targeted inhibition of Müller cell (MC)–produced VEGF or broad inhibition of VEGF
with an intravitreal anti-VEGF antibody reduces intravitreal neovascularization in a rat model
of retinopathy of prematurity (ROP). In this study, we compared the effects of these two
approaches on retinal vascular development and capillary density in the inner and deep plexi
in the rat ROP model.
METHODS. In the rat model of ROP, pups received 1 lL of (1) subretinal lentivector-driven short
hairpin RNA (shRNA) to knockdown MC-VEGFA (VEGFA.shRNA) or control luciferase shRNA,
or (2) intravitreal anti-VEGF antibody (anti-VEGF) or control isotype goat immunoglobulin G
(IgG). Analyses of lectin-stained flat mounts at postnatal day 18 (p18) included: vascular/total
retinal areas (retinal vascular coverage) and pixels of fluorescence/total retinal area (capillary
density) of the inner and deep plexi determined with the Syncroscan microscope, and angles
between cleavage planes of mitotic vascular figures labeled with anti-phosphohistone H3 and
vessel length.
RESULTS. Retinal vascular coverage and density increased in both plexi between p8 and p18 in
room air (RA) pups. Compared with RA, p18 ROP pups had reduced vascular coverage and
density of both plexi. Compared with respective controls, VEGFA.shRNA treatment
significantly increased vascular density in the deep plexus, whereas anti-VEGF reduced
vascular density in the inner and deep plexi. Vascular endothelial growth factor-A.shRNA
caused more cleavage angles predicting vessel elongation and fewer mitotic figures, whereas
anti-VEGF treatment led to patterns of pathologic angiogenesis.
CONCLUSIONS. Targeted treatment with lentivector-driven VEGFA.shRNA permitted physiologic
vascularization of the vascular plexi and restored normal orientation of dividing vascular cells,
suggesting that regulation of VEGF signaling by targeted treatment may be beneficial.
Keywords: VEGF, vascular extent, vascular density, intrvitreal neovscularization, rat model of
retinopathy of prematurity
Lack of retinal capillary support is a pathologic consequencethat precedes intravitreal neovascularization (IVNV) in a
number of diseases, including retinopathy of prematurity (ROP)
and diabetic retinopathy.1,2 Loss of vascular support to the
retina causes hypoxia3,4 and triggers a cascade of events5–7 that
enables transcription of angiogenic factors, including vascular
endothelial growth factor (VEGF),5 erythropoietin,8 angiopoie-
tin,9 and others.10–12 The goals of previous clinical treatments
were to destroy the avascular retina, which was believed
responsible for stimulating angiogenic factor production and to
reduce oxygen debt created by the avascular retina. Later
approaches interfered with angiogenic growth factor-receptor
binding and activation (e.g., antibodies to ligands or receptors
for VEGF, platelet-derived growth factor,13,14 or tyrosine kinase
inhibitors to inhibit signaling pathways) or inhibited inflamma-
tory pathways that also increase angiogenesis (e.g., steroids and
angiotensin II type I receptor).15,16 Currently, efforts seek to
promote physiologic retinal vascularization through the use of
growth factors17 or omega-3 fatty acids in growth-restricted
preterm infants for ROP,18 to prevent metabolic damage to
physiologic vascularization of the retina in diabetic retinopa-
thy,19,20 or to regulate aberrant angiogenic signaling in
endothelial cells to minimize disoriented retinal vascular
growth21 and intravitreal angiogenesis in ROP.22
Recent clinical studies reported a persistent avascular retina
and recurrent IVNV following treatment with nonspecific
intravitreal anti-VEGF agents for severe ROP.23 Using the rat
ROP model, we found that a neutralizing antibody to VEGF
significantly inhibited IVNV but also reduced pup weight gain
and serum VEGF.24 These studies suggest that targeted
inhibition of overproduced VEGF may be a safer strategy to
treat ROP. We located the mRNA signal of VEGFA-splice variants
in the regions corresponding to cellular retinaldehyde-binding
protein (CRALBP)-labeled Müller cells, and therefore developed
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lentivector-driven VEGFA short hairpin RNA (shRNA) to target
Müller cell VEGFA using a CD44 promoter.21 Using the rat ROP
model, we found that the lentivector targeted knockdown of
Müller cell VEGFA significantly inhibited IVNV without
affecting pup weight or serum VEGF. In this study, we
evaluated the safety effects on the retinal vasculature and
capillary density from the two methods of anti-VEGF treatment.
We developed the hypothesis that targeted knockdown of
VEGF in Müller cells that overproduced VEGF21 would
preserve normal-ordered developing intraretinal vasculariza-
tion and capillary density, whereas broad anti-VEGF treatment
would interfere with endothelial cell receptor activation
necessary for physiologic vascularization and cause a persistent
avascular retina with reduced capillary density. We used the rat
model of ROP25 to recreate pathologic features of severe ROP
and measured capillary support in the inner and deep vascular
plexi of the retina by two different methods. We determined
the vascular coverage as areas of vascularized retinal area and
capillary density as pixels fluorescence from lectin-stained flat
mounts showing a vascularized retina in both inner and deep
plexi. In both measurements, outcomes were normalized to
total retinal area. We also determined the number and
orientation of dividing vascular cells within the retina at the
junction of vascularized and avascular retinas. We compared
targeted VEGFA knockdown of Müller cell–VEGFA to neutral-
izing VEGF with an antibody to rat VEGF. Both treatments were
delivered at doses and time points that significantly inhibit
IVNV.21,24,26 Here, we report that targeted VEGFA knockdown
permitted physiologic vascularization of the retinal vascular
plexi and restored normal orientation of dividing vascular cells
at the junction of vascular and avascular retinas. These data
support additional studies to develop methods to target
overproduced VEGF in order to treat IVNV.
METHODS
Rat Model of Oxygen-Induced Retinopathy (Rat
ROP Model)
All animal studies were performed in compliance with the
University of Utah (Guide for the Care and Use of Laboratory
Animals) and the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. The rat ROP model has been
previously described.25 Entire litters of newborn Sprague-
Dawley rat pups (Charles River, Wilmington, MA) and dams
were placed into an oxygen environment that cycled oxygen
concentration between 50% and 10% every 24 hours for 14
days, and then placed into room air (RA). Pup number was
maintained at 12 to 14 pups/litter. At postnatal day 18 (p18),
pups were euthanized by intraperitoneal injection (IP) of
ketamine (60 mg/kg) and xylazine (18 mg/kg) followed by IP
pentobarbital (80 mg/kg).
Ocular Injections
Intravitreal Injections of Neutralizing Antibody to
VEGF. As described previously,24 following anesthesia, 1 lL of
50 ng neutralizing antibody to rat VEGF164 (anti-VEGF; R&D
Systems, Minneapolis, MN) or isotype goat immunoglobulin G
(IgG; R&D Systems) was delivered into the vitreous with a 33-
gauge needle attached to a Hamilton syringe (Hamilton, Reno,
NV) at the beginning of the 50% oxygen cycle on p12 in order
to inhibit retinal secreted VEGF at its highest concentration in
the model at p1426–28 and subsequent IVNV. As shown in our
previous study, 50 ng of neutralizing antibody to rat VEGF164
significantly reduced IVNV by 3.5-fold over IgG control.24
Subretinal Injections of Lentivector-Driven
VEGFA.shRNA. Lentivector-driven VEGFA shRNA was con-
structed and tested as previously described.21 Briefly, shRNAs
were designed as microRNAs against rat VEGFA (VEGFA.shR-
NA) or luciferase (luc.sRNA) and cloned into the lentiviral
transfer vector (pFmCD44.1GW) with the CD44 promoter,
which targets Müller cells and not astrocytes,21,29 and a green
fluorescence protein (GFP) reporter gene. Micron III (Phoenix
Research Laboratories, Inc., Pleasanton, CA) live imaging
showed that 30% of retina was transduced by subretinal
injection of lentivector and achieved 80% knockdown of
retinal VEGFA by VEGFA.shRNA compared with luc.shRNA
determined by ELISA in retinal lysates from the rat model of
ROP. However, an intravitreal injection of lentivirus yielded a
poor retinal virus transduction, which was consistent with the
report from Greenberg et al.29 Vascular endothelial growth
factor A.shRNA effectively reduced IVNV by 4-fold over
luc.shRNA at p18 in the rat model of ROP.21
In this study, at the beginning of the 50% oxygen cycle of
the 50/10 ROP model on p8,21 pups received 1 lL (1 3 109
viral particles/mL) of lentivectors containing VEGFA.shRNA or
luc.shRNA as subretinal injections that created a transient
retinal detachment, which resolved within 24 hours. Both eyes
of each pup were injected with the same lentivector
preparation.
Each litter typically had an equal distribution of either
lentivector preparation. After the injection, topical antibiotic
(0.5% erythromycin) was applied to each eye, and pups were
allowed to recover on a warming pad before being returned to
the Oxycycler.
For both intravitreal and subretinal injections, litters were
typically out of the oxygen cycler for 3 hours. At p18, the time
point of maximum IVNV in this model,26 pups were
euthanized for analysis.
Retinal Flat-Mount Preparation, Imaging, and
Analysis
Lectin-stained retinal flat mounts were prepared using Alexa
Fluor 568–conjugated Griffonia simplicifolia (Bandeiraea)
isolectin B4 (5 lg/mL; Invitrogen, Molecular Probes, Eugene,
OR), as previously described, and imaged30 using an inverted
fluorescence microscope (Olympus, Tokyo, Japan). Flat
mounts were created using the scan-slide stitching function
of Metamorph imaging software (Molecular Devices, Inc.,
Sunnyvale, CA). Measurements were made by two masked
reviewers using ImageJ (National Institutes of Health, Bethes-
da, MD). High resolution multi-Z plane images of retinal flat
mounts were created by autostitching individual 203 fluores-
cence images of lectin-stained vasculature using the Syncro-
scan fluorescence microscope (Olympus). Fluorescence was
converted to grayscale prior to stitching of each Z plane. The
number of Z-planes needed to capture both primary and
tertiary plexi was determined during imaging. The inner
(primary plexus) and deep (tertiary plexus) layers were
separated using filters in Adobe Photoshop CS5 extended
(Version 12.1; Adobe Systems, Inc., San Jose, CA). In this study,
only data from the inner and deep capillary layers were
analyzed. Images corresponding to inner and deep layers had
different color channels in Photoshop (Adobe Systems, Inc.) to
differentiate the inner and deep layers. Total pixels covered by
inner and deep layers were measured using histograms in
Photoshop. The flat-mount vascular and avascular areas were
measured by ImageJ 1.45S (National Institutes of Health).
Retinal vascular coverage was defined as area of vascular extent
to total retina area. Retinal vascular density was the pixels of
lectin fluorescence to total retinal area.
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Phosphohistone Labeling and Measurement of
Mitoses and Cleavage Angles
Quantitative image analysis was performed using the freeware
ImageTool, version 3 (University of Texas, Austin, TX). As
described previously,31 cell division cleavage planes were
identified in Alexa Fluor 568–conjugated isolectin-stained
vessels by bisection of the separating chromosomes labeled
with Alexa Fluor 488–conjugated anti-phosphohistone H3 (10
lg/mL; EMD Millipore, Billerica, MA) during late metaphase to
anaphase. Mitotic figures were identified as cells labeled with
isolectin and phosphohistone H3. Lines were drawn using
image management software (Photoshop 7.0; Adobe Systems,
Inc.) along the cleavage plane and along the long axis of the
blood vessel for each mitotic division. The angle between these
two lines was calculated. Angles of 08 predicted widening and
908 elongation of vessels.31 Angles between these values
predict disordered divisions.
Statistical Analysis
Significant differences between treatment groups were deter-
mined by ANOVA. A minimum value of P less than 0.05 was
considered statistically significant. At least two different litters
were used for each experiment to account for potential effects
within individual litters. For each condition, three to five flat
mounts were analyzed. For each analysis, one data point was
one eye from an individual pup.
RESULTS
Retinal Vascular Coverage and Density in the Inner
and Deep Plexi at Different Time Points During
Development
To analyze retinal vascular development in inner and deep
plexi at various time points in development, we used two
different approaches. In the first, we measured the extent of
FIGURE 1. Retinal vascular coverage and density in the inner and deeper plexi are increased during development at p8, p10, p14, and p18 in RA. (A)
Syncroscan images of lectin-stained retinal flat mounts. (B) A portion of p18 VEGFA.shRNA-treated flat mount in the ROP model showing inner
plexus, deep plexus, and combined image of both plexi assigned different colors (inner-red, deep-green; inner and deep plexi offset to permit
visualization; lines indicate magnification size at the same unit). (C) Vascular coverage determined by vascular area normalized to total retina area.
(D) Vascular density determined by the number of pixels of lectin fluorescence normalized to total retinal area (overall one-way ANOVA ***P <
0.001; results are means 6 SD).
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the retina covered by blood vessels as vascular/total retinal
area for each plexus (termed vascular coverage) in retinal flat
mounts (Fig. 1A). In the second, we measured the number of
pixels of lectin-stained fluorescence/total retinal area in the
inner and deep vascular plexi (termed vascular density),
separated by assigning different colors to the plexi (Fig. 1B).
The second approach measures not only retinal vascular/total
retinal area, but incorporates capillary density/total retinal
area. At time points from p8 to p18 in RA-raised rats, we
found vascular coverage increased on average 1.5-fold in the
inner plexus and 3.5-fold in the deep plexus (Fig. 1C).
Vascular density increased 3.5-fold in the inner plexus and 6-
fold in the deep plexus from p8 to p18 (Fig. 1D). Even though
the slope of vascular coverage of the deep plexus was steeper
than that of the inner plexus at the time points measured, the
vascular density of the deep plexus increased with a similar
slope as the inner plexus, suggesting that maintaining
capillary density may be important to overall retinal
development.
Retinal Vascular Coverage and Density in the Inner
and Deep Plexi is Reduced in the Rat ROP Model
Delayed physiological retinal vascular development accounts
for much of the avascular retina in phase I ROP in places in
which oxygen is regulated.32 When rat pups are exposed to the
ROP model, retinal vascular coverage in the inner and deep
plexi was decreased compared with RA-raised pups at p18
(Figs. 2A, 2B).33 At p18, RA vascular coverage in both inner and
deep plexi was 96% on average; however, for pups exposed to
the ROP model, both vascular coverage (Fig. 2B) and vascular
density (Fig. 2C) were significantly reduced in both inner and
deep plexi compared with RA-raised pups.
Effects of Methods to Inhibit VEGF on Vascular
Density and the Extent of Vascular Coverage in
Inner and Deep Plexi
We tested two different methods to reduce VEGF at doses
previously found to successfully inhibit VEGF-induced
IVNV.21,24,26 In one, intravitreal anti-VEGF antibody (anti-VEGF)
was compared with its control nonimmune IgG and in the
other a subretinal injection of lentivectors carrying VEGFA
shRNA (VEGFA.shRNA) that knocked down Müller cell VEGF
was compared with control shRNA to the nonmammalian
gene, luciferase (luc.shRNA). We measured vascular coverage
and vascular density of the inner and deep plexi in lectin
stained flat mounts at p18 ROP (Fig. 3). Compared with
respective controls, luc.shRNA or IgG-treated ROP pups,
VEGFA.shRNA or anti-VEGF did not significantly affect vascular
coverage in the inner and deep plexi (Fig. 4A). However,
compared with respective controls, anti-VEGF significantly
reduced vascular density of the inner and deep plexus, and
VEGFA.shRNA treatment significantly increased vascular den-
sity of the deep plexus (Fig. 4B). Therefore, compared with
respective controls, anti-VEGF treatment reduced capillary
density in the inner and deep plexi of the retina in the ROP
model, and targeted knockdown of VEGFA increased vascular
density in the deep plexus, even though both treatments had
no effect on the vascular coverage.
FIGURE 2. Retinal vascular coverage and density are reduced in both inner and deep plexi of pups raised in the ROP model at p18. (A) Images of
retinal flat mounts of pups raised in RA or exposed to the ROP model. (B) Retinal vascular coverage and (C) retinal vascular density in the inner and
deep plexi (*P < 0.05, ***P < 0.001 versus RA, two-way ANOVA; results are means 6 SD).
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Effects of Targeted VEGF Knockdown and Anti-
VEGF on Number and Angle of Proliferating
Vascular Endothelial Cells
The orientation of dividing endothelial cells predicts whether
the subsequent vessel is elongated, widened, or disordered.31
Previously, we found that excessive signaling through VEGFR2
disordered the orientation of dividing daughter endothelial
cells in an embryonic stem cell model31 and vascular cells
leading to increased vessel tortuosity in the ROP model.34
Knockdown of Müller cell VEGFA with shRNA appeared to
reduce retinal vascular tortuosity (Fig. 3) that occurred in the
ROP model compared with anti-VEGF antibody post treatment.
We, therefore, postulated that targeted VEGFA knockdown in
Müller cells would orient dividing endothelial cells into a more
ordered physiologic pattern. To test this, we labeled retinal flat
mounts from pups in the ROP model after treatment with
VEGFA.shRNA, luc.shRNA, anti-VEGF, or IgG with lectin, and
an antibody to anti-phosphohistone H3 that manifests mitotic
figures in anaphase. We counted the number of mitotic figures
and also determined the cleavage angles between the long axis
of lectin-labeled vessels and the cleavage plane drawn between
phosphohistone H3–labeled figures (Figs. 5A, 5B). We predict-
ed that cleavage angles between the cleavage planes of dividing
cells and respective long axes of the vessels would align closer
to 908 (predicting elongation or physiologic angiogenesis31;
Fig. 5A) with targeted VEGFA knockdown, whereas angles
away from 908 (predictive of widening or disordered angio-
genesis; Fig. 5B) would occur after nonspecific anti-VEGF
treatment.
We clustered angles into groups every 158 between 08 and
908, and determined the absolute number of antiphosphohis-
tone H3–labeled cells at the plane of the inner and deep plexi
counted throughout retinal flat mounts. Most mitotic figures
were found at the junctions between vascularized and
FIGURE 3. Vascular endothelial growth factor-A.shRNA versus anti-VEGF treatments on retinal vascular morphology. Images of lectin-stained retinal
flat mounts from pups treated with luc.shRNA, VEGFA.shRNA, IgG, and anti-VEGF at p18 in the ROP model.
FIGURE 4. Retinal vascular coverage and density in the inner and deep
plexi of pups treated with VEGFA.shRNA or anti-VEGF in the ROP model
at p18 compared with respective controls. (A) Retinal vascular coverage
and (B) vascular density (*P < 0.05 versus luc.shRNA; ††P < 0.01 and
†††P < 0.001 versus IgG, two-way ANOVA; results are means 6 SD).
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avascular retina where IVNV occurs. Compared with luc.shR-
NA, we found that VEGFA.shRNA treatment caused more
mitotic figures clustered between 608 and 908, predicting
elongation and ordered angiogenesis (Fig. 5C). We also found
that the absolute number of dividing vascular cells was
decreased following VEGFA.shRNA treatment compared with
luc.shRNA (Fig. 5D). There was no difference in the percent of
mitotic figures clustered between 608 and 908 and total mitotic
figures between anti-VEGF and IgG (Figs. 5C, 5D). In
agreement with this, retinal flat mounts of inner plexi after
each treatment and respective controls provided evidence that
targeted overproduction of VEGF restored more normal retinal
vascular morphology than did broad anti-VEGF inhibition (Fig.
3). Altogether, these data provide evidence that targeting
overproduced VEGFA with the VEGFA.shRNA treatment
restored ordered angiogenesis, whereas anti-VEGF treatment
did not improve ordered angiogenesis.
DISCUSSION
In countries lacking resources to treat severe ROP, the use of
intravitreal anti-VEGF antibodies has increased. However, there
have been some reports of persistent avascular retina,
recurrent IVNV, retinal detachment,23,35,36 and reduction in
serum VEGF leading to concern about potential effects of
intravitreal anti-VEGF on growth and development of preterm
infants. The current guidelines for ROP treatment recommend
longer follow-up after anti-VEGF treatment than for standard of
care laser and only use of anti-VEGF agents for zone I stage 3þ
severe ROP until more information on proper dose and safety is
available.37–39
Many studies report inner plexus coverage determined by
area of vascular extent as an outcome, whereas fewer have
measured capillary density or the vascular extent of both
inner and deep plexi.40 In this study, we sought to determine
the effects of different strategies to inhibit VEGF on
physiologic retinal vascularization by measuring the intensity
of pixel fluorescence of the inner and deep plexi in lectin-
stained retinal flat mounts, which provided data on capillary
density and extent of these plexi. Compared with RA-raised
pups of the same developmental age, we found that the ROP
model reduced vascular extent and density compared with
normal development. This finding goes along with a previous
study in which retinal hypoxia measured with Hypoxyprobe
(HPI, Burlington, MA), which detects tissue where oxygen
levels are approximately 1%, was increased in retinal flat
mounts from p18 rat pups in the ROP model compared with
FIGURE 5. Vascular endothelial growth factor-A.shRNA treatment reduces disordered angiogenesis in the ROP model. Diagram of cleavage angles
produced from lectin-stained flat mounts colabeled for phosphohistone H3 showing cells in anaphase: (A) cleavage angles between 608 and 908
predict ordered angiogenesis; (B) cleavage angles between 08 and 608 predict widened or disordered angiogenesis; (C) percentage of vascular cells
with cleavage angles between 608 and 908; and (D) total number of mitotic figures determined as phosphohistone H3–labeled vascular cells in
retinal flat mounts from pups treated with luc.shRNA, VEGFA.shRNA, IgG, or anti-VEGF (*P < 0.05 versus luc.shRNA, two-way ANOVA; results are
means 6 SD).
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RA-raised pups.41 Although vascular extent after treatment
with either strategy to reduce VEGF was no different
compared to untreated ROP, broad inhibition using an
intravitreal antibody against rat VEGF at a dose shown to
inhibit IVNV in the rat ROP model24,26 significantly reduced
capillary density in both inner and deep retinal plexi
compared with control IgG. In contrast, targeted VEGFA
knockdown in Müller cells that overproduce VEGF increased
capillary density in the deep plexus and did not inhibit
capillary density in the inner plexus compared with
luc.shRNA control. Vascular endothelial growth factor is a
survival factor for endothelial cells and broad anti-VEGF
needed to neutralize excess VEGF may adversely reduce VEGF
essential to the survival of newly developed intraretinal
capillaries.42 Vascular endothelial growth factor also has
survival effects on retinal neurons and Müller glia,43 and it
is increasingly clear that neurovascular interactions are
important in retinovascular development and angiogene-
sis.40,44–46
Finally, we found that the number of dividing vascular cells
was increased following treatment with anti-VEGF and the
orientation of dividing cells predicted vessel widening or
disordered angiogenesis instead of more physiologic elonga-
tion. If vascular cell divisions are disordered, they may divide
outside the plane of the retina and into the vitreous as IVNV.
Even though the change in area of IVNV was comparable after
treatment with intravitreal anti-VEGF24 or subretinal VEG-
FA.shRNA21 compared with respective controls at p18 in the
ROP model, it is possible that hypoxia from reduced capillary
density was greater after anti-VEGF antibody and may have
stimulated later recurrent intravitreal angiogenesis reported at
p25.24 These findings may also lend insight into what occurs in
some cases of human ROP when recurrent intravitreal
angiogenesis occurs after treatment with intravitreal anti-VEGF
antibody.
In summary, we show that broad inhibition of VEGF was
associated with reduced capillary density and may have led to
disordered angiogenesis from retina that had too little capillary
support and oxygenation. The data from these studies support
the need for both greater knowledge of the effect of dose on
developing angiogenesis as it relates to ROP as well as to future
studies into targeted treatment of disordered angiogenesis
causing IVNV.
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